NCT05706129View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

March 31, 2029

Conditions
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Urothelial Carcinoma (UC)Indeterminate Renal Mass (IDRM)Muscle Invasive Bladder Cancer (MIBC)Head and Neck Cancer (H&N)Triple Negative Breast Cancer (TNBC)Squamous Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

[68Ga]Ga-DPI-4452

\[68Ga\]Ga-DPI-4452, administered as IV injection.

DRUG

[177Lu]Lu-DPI-4452

\[177Lu\]Lu-DPI-4452, administered as IV infusion.

Trial Locations (10)

13005

RECRUITING

AP-HM - Hopital de la Timone, Marseille

21079

RECRUITING

Centre Georges François Leclerc, Dijon

31100

RECRUITING

IUCT - Oncopole, Toulouse

38043

RECRUITING

CHU de Grenoble-Alpes, Boulevard de la Chantourne, Grenoble

44093

RECRUITING

CHU de Nantes, Nantes

54511

RECRUITING

CHRU de Nancy - Hopitaux de Brabois, Vandœuvre-lès-Nancy

63011

RECRUITING

Centre Jean Perrin, Clermont-Ferrand

69373

RECRUITING

Centre Léon Bérard, Lyon

VIC 3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

NSW 2010

RECRUITING

UNSW Sydney, St Vincent's Hospital Sydney, Sydney

All Listed Sponsors
lead

ITM Oncologics GmbH

INDUSTRY